Back to discover
Disease
Thyroid gland carcinoma
Late-stage therapeutic development
Also known as carcinoma of the thyroid, carcinoma of the thyroid gland, carcinoma of thyroid, carcinoma of thyroid gland+5 more
carcinoma of the thyroid, carcinoma of the thyroid gland, carcinoma of thyroid, carcinoma of thyroid gland, thyroid carcinoma, cancer of the thyroid, cancer of thyroid, head and neck cancer, thyroid, thyroid gland cancer.
18
Clinical trials
12
Associated genes
4
Related proteins
Current focus
Osteocalcin biologyPro-neuregulin-1 biologyTherapeutic development
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
- Q2 2027Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck
- Q3 2027Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas
- Q3 2027Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
- Q3 2028A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer
- Q3 2030A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600Em
Major developments
Upcoming trial readoutHigh impact
Results expected Q3 20302026-06-18
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-06-26A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid CancerResults expected Q3 2028
- 2026-06-18A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600EmResults expected Q3 2030
- 2026-05-22Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer and Other Malignancies of the Head and NeckResults expected Q2 2027
- 2026-02-17Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerResults expected Q3 2027
- 2026-01-09Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid CarcinomasResults expected Q3 2027
Activity timeline7
- 2026-06-26ClinicalA Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid CancerResults expected Q3 2028
- 2026-06-18ClinicalA Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600EmResults expected Q3 2030
- 2026-06-17ClinicalPhase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted TherapyResults posted
- 2026-05-22ClinicalPilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer and Other Malignancies of the Head and NeckResults expected Q2 2027
- 2026-05-08ClinicalA Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsTerminated
- 2026-02-17ClinicalLenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerResults expected Q3 2027
- 2026-01-09ClinicalAtezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid CarcinomasResults expected Q3 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Cabozantinibapproved
Accelerated approval — Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for advanced renal cell… (2016)
Sorafenibapproved
Approval — Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcino… (2006)
Thyrotropin alfaapproved
Approval — Thyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radio… (2000)
Clinical trials
The current development programme across all trial phases.
Clinical programme
18
6
1
6
Late-stage studies
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
First approvals
2016emaAccelerated approval — Cabozantinib· Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for advanced renal cell carcinoma as first-line treatment of adult patients with intermediate or poor risk, in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. Hepatocellular carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.Differentiated thyroid carcinoma (DTC)Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.Neuroendocrine Tumours (NET)Cabometyx is indicated for the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues. source ↗
2014emaApproval — Cabozantinib· Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. source ↗
2006emaApproval — Sorafenib· Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine. source ↗
2000emaApproval — Thyrotropin alfa· Thyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (THST). Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh (recombinant human) TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels. Thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mCi (1.1 GBq) to 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.4). source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
carcinoma of the thyroid, carcinoma of the thyroid gland, carcinoma of thyroid, carcinoma of thyroid gland, thyroid carcinoma, cancer of the thyroid, cancer of thyroid, head and neck cancer, thyroid, thyroid gland cancer
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.